Heart failure and mitochondrial dysfunction: The role of mitochondrial fission/fusion abnormalities and new therapeutic strategies

Anne A Knowlton, Le Chen, Zulfiqar A. Malik

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

ABSTRACT:: The treatment of heart failure (HF) has evolved during the past 30 years with the recognition of neurohormonal activation and the effectiveness of its inhibition in improving the quality of life and survival. Over the past 20 years, there has been a revolution in the investigation of the mitochondrion with the development of new techniques and the finding that mitochondria are connected in networks and undergo constant division (fission) and fusion, even in cardiac myocytes. This has led to new molecular and cellular discoveries in HF, which offer the potential for the development of new molecular-based therapies. Reactive oxygen species are an important cause of mitochondrial and cellular injury in HF, but there are other abnormalities, such as depressed mitochondrial fusion, that may eventually become the targets of at least episodic treatment. The overall need for mitochondrial fission/fusion balance may preclude sustained change in either fission or fusion. In this review, we will discuss the current HF therapy and its impact on the mitochondria. In addition, we will review some of the new drug targets under development. There is potential for effective, novel therapies for HF to arise from new molecular understanding.

Original languageEnglish (US)
Pages (from-to)196-206
Number of pages11
JournalJournal of Cardiovascular Pharmacology
Volume63
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Mitochondrial Dynamics
Heart Failure
Mitochondria
Therapeutics
Treatment Failure
Cardiac Myocytes
Reactive Oxygen Species
Quality of Life
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • ACE inhibitor
  • Cardiovascular
  • Heart
  • Metformin
  • Mitochondria
  • Mitochondrial fission
  • Mitochondrial fusion
  • Ss-31

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Heart failure and mitochondrial dysfunction : The role of mitochondrial fission/fusion abnormalities and new therapeutic strategies. / Knowlton, Anne A; Chen, Le; Malik, Zulfiqar A.

In: Journal of Cardiovascular Pharmacology, Vol. 63, No. 3, 2014, p. 196-206.

Research output: Contribution to journalArticle

@article{d9a00658029245b9a6cb519f97c3e66e,
title = "Heart failure and mitochondrial dysfunction: The role of mitochondrial fission/fusion abnormalities and new therapeutic strategies",
abstract = "ABSTRACT:: The treatment of heart failure (HF) has evolved during the past 30 years with the recognition of neurohormonal activation and the effectiveness of its inhibition in improving the quality of life and survival. Over the past 20 years, there has been a revolution in the investigation of the mitochondrion with the development of new techniques and the finding that mitochondria are connected in networks and undergo constant division (fission) and fusion, even in cardiac myocytes. This has led to new molecular and cellular discoveries in HF, which offer the potential for the development of new molecular-based therapies. Reactive oxygen species are an important cause of mitochondrial and cellular injury in HF, but there are other abnormalities, such as depressed mitochondrial fusion, that may eventually become the targets of at least episodic treatment. The overall need for mitochondrial fission/fusion balance may preclude sustained change in either fission or fusion. In this review, we will discuss the current HF therapy and its impact on the mitochondria. In addition, we will review some of the new drug targets under development. There is potential for effective, novel therapies for HF to arise from new molecular understanding.",
keywords = "ACE inhibitor, Cardiovascular, Heart, Metformin, Mitochondria, Mitochondrial fission, Mitochondrial fusion, Ss-31",
author = "Knowlton, {Anne A} and Le Chen and Malik, {Zulfiqar A.}",
year = "2014",
doi = "10.1097/01.fjc.0000432861.55968.a6",
language = "English (US)",
volume = "63",
pages = "196--206",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Heart failure and mitochondrial dysfunction

T2 - The role of mitochondrial fission/fusion abnormalities and new therapeutic strategies

AU - Knowlton, Anne A

AU - Chen, Le

AU - Malik, Zulfiqar A.

PY - 2014

Y1 - 2014

N2 - ABSTRACT:: The treatment of heart failure (HF) has evolved during the past 30 years with the recognition of neurohormonal activation and the effectiveness of its inhibition in improving the quality of life and survival. Over the past 20 years, there has been a revolution in the investigation of the mitochondrion with the development of new techniques and the finding that mitochondria are connected in networks and undergo constant division (fission) and fusion, even in cardiac myocytes. This has led to new molecular and cellular discoveries in HF, which offer the potential for the development of new molecular-based therapies. Reactive oxygen species are an important cause of mitochondrial and cellular injury in HF, but there are other abnormalities, such as depressed mitochondrial fusion, that may eventually become the targets of at least episodic treatment. The overall need for mitochondrial fission/fusion balance may preclude sustained change in either fission or fusion. In this review, we will discuss the current HF therapy and its impact on the mitochondria. In addition, we will review some of the new drug targets under development. There is potential for effective, novel therapies for HF to arise from new molecular understanding.

AB - ABSTRACT:: The treatment of heart failure (HF) has evolved during the past 30 years with the recognition of neurohormonal activation and the effectiveness of its inhibition in improving the quality of life and survival. Over the past 20 years, there has been a revolution in the investigation of the mitochondrion with the development of new techniques and the finding that mitochondria are connected in networks and undergo constant division (fission) and fusion, even in cardiac myocytes. This has led to new molecular and cellular discoveries in HF, which offer the potential for the development of new molecular-based therapies. Reactive oxygen species are an important cause of mitochondrial and cellular injury in HF, but there are other abnormalities, such as depressed mitochondrial fusion, that may eventually become the targets of at least episodic treatment. The overall need for mitochondrial fission/fusion balance may preclude sustained change in either fission or fusion. In this review, we will discuss the current HF therapy and its impact on the mitochondria. In addition, we will review some of the new drug targets under development. There is potential for effective, novel therapies for HF to arise from new molecular understanding.

KW - ACE inhibitor

KW - Cardiovascular

KW - Heart

KW - Metformin

KW - Mitochondria

KW - Mitochondrial fission

KW - Mitochondrial fusion

KW - Ss-31

UR - http://www.scopus.com/inward/record.url?scp=84896316994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896316994&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000432861.55968.a6

DO - 10.1097/01.fjc.0000432861.55968.a6

M3 - Article

C2 - 23884159

AN - SCOPUS:84896316994

VL - 63

SP - 196

EP - 206

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -